309 related articles for article (PubMed ID: 34801581)
1. Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts.
Marfella R; D'Onofrio N; Trotta MC; Sardu C; Scisciola L; Amarelli C; Balestrieri ML; Grimaldi V; Mansueto G; Esposito S; D'Amico M; Golino P; Signoriello G; De Feo M; Maiello C; Napoli C; Paolisso G
Metabolism; 2022 Feb; 127():154936. PubMed ID: 34801581
[TBL] [Abstract][Full Text] [Related]
2. Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients.
Marfella R; Amarelli C; Cacciatore F; Balestrieri ML; Mansueto G; D'Onofrio N; Esposito S; Mattucci I; Salerno G; De Feo M; D'Amico M; Golino P; Maiello C; Paolisso G; Napoli C
J Am Coll Cardiol; 2020 Mar; 75(11):1249-1262. PubMed ID: 32192650
[TBL] [Abstract][Full Text] [Related]
3. Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD.
Hussain S; Khan AW; Akhmedov A; Suades R; Costantino S; Paneni F; Caidahl K; Mohammed SA; Hage C; Gkolfos C; Björck H; Pernow J; Lund LH; Lüscher TF; Cosentino F
Circ Res; 2020 Oct; 127(10):1261-1273. PubMed ID: 32815777
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes.
Marfella R; Scisciola L; D'Onofrio N; Maiello C; Trotta MC; Sardu C; Panarese I; Ferraraccio F; Capuano A; Barbieri M; Balestrieri ML; Napoli C; Paolisso G
Pharmacol Res; 2022 Oct; 184():106448. PubMed ID: 36096423
[TBL] [Abstract][Full Text] [Related]
5. Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy.
Costantino S; Akhmedov A; Melina G; Mohammed SA; Othman A; Ambrosini S; Wijnen WJ; Sada L; Ciavarella GM; Liberale L; Tanner FC; Matter CM; Hornemann T; Volpe M; Mechta-Grigoriou F; Camici GG; Sinatra R; Lüscher TF; Paneni F
Eur Heart J; 2019 Mar; 40(12):997-1008. PubMed ID: 30629164
[TBL] [Abstract][Full Text] [Related]
6. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: A clinical and experimental study.
Mora-Fernández C; Sánchez-Niño MD; Donate-Correa J; Martín-Núñez E; Pérez-Delgado N; Valiño-Rivas L; Fernández-Fernández B; Ortiz A; Navarro-González JF
Biomed Pharmacother; 2022 Oct; 154():113677. PubMed ID: 36942605
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of sodium glucose cotransporter 2 inhibitors on left ventricular mass in patients with diabetes mellitus.
Kosugi D; Inaba H; Kaido Y; Ito S; Hirobata T; Toyofuku M; Matsuoka T; Inoue G
J Diabetes; 2021 Nov; 13(11):847-856. PubMed ID: 34231959
[TBL] [Abstract][Full Text] [Related]
12. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms.
Huang K; Luo X; Liao B; Li G; Feng J
Cardiovasc Diabetol; 2023 Apr; 22(1):86. PubMed ID: 37055837
[TBL] [Abstract][Full Text] [Related]
13. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor δ (PPARδ): from bedside to bench.
Chang WT; Cheng JT; Chen ZC
Cardiovasc Diabetol; 2016 Aug; 15(1):113. PubMed ID: 27519769
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
D'Onofrio N; Sardu C; Trotta MC; Scisciola L; Turriziani F; Ferraraccio F; Panarese I; Petrella L; Fanelli M; Modugno P; Massetti M; Marfella LV; Sasso FC; Rizzo MR; Barbieri M; Furbatto F; Minicucci F; Mauro C; Federici M; Balestrieri ML; Paolisso G; Marfella R
Mol Metab; 2021 Dec; 54():101337. PubMed ID: 34500107
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases.
Al-Shamasi AA; Elkaffash R; Mohamed M; Rayan M; Al-Khater D; Gadeau AP; Ahmed R; Hasan A; Eldassouki H; Yalcin HC; Abdul-Ghani M; Mraiche F
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884494
[TBL] [Abstract][Full Text] [Related]
17. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Joubert M; Jagu B; Montaigne D; Marechal X; Tesse A; Ayer A; Dollet L; Le May C; Toumaniantz G; Manrique A; Charpentier F; Staels B; Magré J; Cariou B; Prieur X
Diabetes; 2017 Apr; 66(4):1030-1040. PubMed ID: 28052965
[TBL] [Abstract][Full Text] [Related]
18. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.
Wang L; Cai Y; Jian L; Cheung CW; Zhang L; Xia Z
Cardiovasc Diabetol; 2021 Jan; 20(1):2. PubMed ID: 33397369
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
Castañeda AM; Dutra-Rufato A; Juarez MJ; Grosembacher L; Gonzalez-Torres H; Musso CG
Int Urol Nephrol; 2021 Feb; 53(2):291-299. PubMed ID: 32767250
[TBL] [Abstract][Full Text] [Related]
20. Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes.
Nazari S; Mirkhani H
Curr Diabetes Rev; 2023; 19(8):e221222212126. PubMed ID: 36567296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
